| 1 minute

MedAnnex Ltd Receives SMART: Scotland R&D Award

Scottish Enterprise will contribute up to £423,000 towards the industrial development of a novel antibody to treat autoimmune diseases

Edinburgh, UK, 12 June 2018: MedAnnex Ltd, an innovative biotechnology company developing new therapies to treat autoimmune diseases, announced today that it has been awarded up to £423,000 via the SMART: SCOTLAND programme. Alongside backing from MedAnnex’s investors, this Scottish Enterprise award will co-fund critical industrial development work for the company’s novel antibody, annexuzlimab, which has the potential to become a ground-breaking autoimmune disease therapy.

In most cases, autoimmune diseases are life-changing, with high medical, social and financial burdens. Patients often develop resistance to existing therapies, many of which have serious side-effects, so there is an urgent need for new treatments.

To read the full article, click here. 

Find out more about business support in Scotland here. 

Back to News

Do you have news for the Scottish Life Sciences Community?

Submit Your Own News